Federal health officials recently added new clinical guidance on the potential for myocarditis after COVID-19 vaccination for adolescents and young adults.
The statement, signed by the leaders...
Gilead recently announced that its COVID-19 treatment, remdesivir, lowered the risk for mortality compared with matched controls in patients hospitalized with the virus.
The three real-world data...
The Biden Administration will invest over $3 billion to accelerate the discovery, development, and manufacturing of COVID-19 antiviral medicines.
The initiative, called the Antiviral Program for...
New data showed that Pfizer’s tofacitinib elicited a lower cumulative incidence of death or respiratory failure through day 28 compared to placebo in COVID-19 patients hospitalized with...
Novavax has announced that its COVID-19 vaccine, NVX-CoV2373, demonstrated 100 percent protection against moderate or severe illness and 90.4 percent efficacy overall in a Phase 3 clinical...
FDA recently updated its letter of authorization for Johnson & Johnson’s COVID-19 vaccine to help facilitate potential export to other countries.
Under the revised letter, FDA...
Pfizer and BioNTech will provide the US government with 500 million doses of their COVID-19 vaccine; the allotment includes 200 million doses in 2021 and 300 million doses in 2022 at a not-for-profit...
Merck and Sanofi recently announced that their six-in-one combination pediatric vaccine is now available throughout the US.
Vaxelis is the first and only hexavalent combination vaccine available...
Moderna and UNICEF recently signed a long-term agreement for the supply of COVID-19 vaccine on behalf of the COVAX Facility, part of the agreement announced in May.
UNICEF and its procurement...
Moderna recently announced that it initiated the rolling submission process for a Biologics License Application (BLA) for its mRNA COVID-19 vaccine.
The company will continue to submit data to support...
Moderna and Aldevron recently expanded their partnership to support Moderna’s mRNA COVID-19 vaccine and clinical development therapeutic pipeline.
Aldevron is a provider of plasmid DNA,...
AstraZeneca’s COVID-19 vaccine, Vaxzevria, was recently granted emergency use in Japan for active immunization of individuals 18 years of age and older.
The Japanese Ministry of Health,...
Moderna recently announced that the Phase 2/3 study of its COVID-19 vaccine in adolescents met its primary immunogenicity endpoint, successfully bridging immune response to the adult...
Medicago’s Coronavirus-Like Particle COVID-19 Vaccine Candidate (CoVLP) elicited significant humoral immune response across all age groups when administered in combination with GSK’s...
GSK and Sanofi’s COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses in a Phase 2 clinical trial, according to a recent press release.
The Phase 2 trial enrolled...
A multisite test-negative design case-control CDC study recently found that the mRNA COVID-19 vaccines from Pfizer and Moderna are highly effective against symptomatic coronavirus.
The study analyzed...
Moderna recently announced a supply agreement with the government of Australia for 25 million doses of its mRNA COVID-19 vaccine and booster variant candidate.
Ten million doses of...
EMA’s safety committee recently reviewed a number of risk and safety signals related to various COVID-19 vaccines
First, the committee known as PRAC (Pharmacovigilance Risk Assessment Committee)...
Pfizer and BioNTech recently announced the initiation of a Biologics License Application for full FDA approval of their mRNA COVID-19 vaccine
With the application, the companies submitted data t from...
FDA recently expanded the emergency use authorization for the Pfizer COVID-19 vaccine to include adolescents 12 through 15 years of age.
The agency amended the original emergency use authorization...
